DrugPatentWatch Database Preview
Ranbaxy Company Profile
» See Plans and Pricing
What is the competitive landscape for RANBAXY, and when can generic versions of RANBAXY drugs launch?
RANBAXY has forty-five approved drugs.
There is one US patent protecting RANBAXY drugs. There are fifteen tentative approvals on RANBAXY drugs.
There are eighteen patent family members on RANBAXY drugs in eighteen countries and seventy-six supplementary protection certificates in fifteen countries.
Summary for Ranbaxy
International Patents: | 18 |
US Patents: | 1 |
Tradenames: | 33 |
Ingredients: | 29 |
NDAs: | 45 |
Patent Litigation for Ranbaxy: | See patent lawsuits for Ranbaxy |
PTAB Cases with Ranbaxy as petitioner: | See PTAB cases with Ranbaxy as petitioner |
Drugs and US Patents for Ranbaxy
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ranbaxy Labs Ltd | PANIXINE DISPERDOSE | cephalexin | TABLET, FOR SUSPENSION;ORAL | 065100-001 | Sep 11, 2003 | DISCN | No | No | Start Trial | Start Trial | |||||
Ranbaxy | RANITIDINE HYDROCHLORIDE | ranitidine hydrochloride | TABLET;ORAL | 075254-001 | Jan 14, 2000 | DISCN | No | No | Start Trial | Start Trial | |||||
Ranbaxy Labs Ltd | CEFPROZIL | cefprozil | TABLET;ORAL | 065198-002 | Dec 13, 2006 | DISCN | No | No | Start Trial | Start Trial | |||||
Ranbaxy | AVENTYL | nortriptyline hydrochloride | SOLUTION;ORAL | 014685-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | Start Trial | Start Trial | |||||
Ranbaxy | HYDROCODONE BITARTRATE AND ACETAMINOPHEN | acetaminophen; hydrocodone bitartrate | TABLET;ORAL | 040824-001 | Aug 16, 2007 | DISCN | No | No | Start Trial | Start Trial | |||||
Ranbaxy Labs Ltd | PANIXINE DISPERDOSE | cephalexin | TABLET, FOR SUSPENSION;ORAL | 065100-002 | Sep 11, 2003 | DISCN | No | No | Start Trial | Start Trial | |||||
Ranbaxy Labs Ltd | CEFPROZIL | cefprozil | FOR SUSPENSION;ORAL | 065202-002 | Jun 30, 2006 | DISCN | No | No | Start Trial | Start Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Ranbaxy
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Ranbaxy | AVENTYL | nortriptyline hydrochloride | SOLUTION;ORAL | 014685-001 | Approved Prior to Jan 1, 1982 | 3,922,305 | Start Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Ranbaxy Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Iceland | 6709 | Start Trial |
Poland | 365135 | Start Trial |
New Zealand | 524519 | Start Trial |
Russian Federation | 2003104808 | Start Trial |
Canada | 2416767 | Start Trial |
Israel | 154307 | Start Trial |
Australia | 7659801 | Start Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Ranbaxy Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1429780 | SPC/GB12/058 | United Kingdom | Start Trial | PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003 |
1506211 | PA2014026 | Lithuania | Start Trial | PRODUCT NAME: DAPAGLIFOZINUM + METFORMINUM; REGISTRATION NO/DATE: EU/1/13/900 20140116 |
1730131 | C01730131/02 | Switzerland | Start Trial | PRODUCT NAME: EMPAGLIFLOZIN UND METFORMINHYDROCHLORID; REGISTRATION NO/DATE: SWISSMEDIC 65570 12.11.2015 |
1412357 | CA 2008 00035 | Denmark | Start Trial | PRODUCT NAME: SITAGLIPTIN VALGFRIT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, ISAER MONOPHOSPHAT, METFORMIN VALGFRIT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, ISAER HYDROCHLORID |
1506211 | C300677 | Netherlands | Start Trial | PRODUCT NAME: COMBINATIE VAN DAPAGLIFLOZINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN METFORMINE OF EEN FARMACEITISCH AANVAARDBAAR ZOUT DAARVAN, ZOALS BESCHERMD DOOR HET BASISOCTROOI EP 1506211B1; REGISTRATION NO/DATE: EU/1/13/900 20140121 |
1506211 | 300677 | Netherlands | Start Trial | PRODUCT NAME: COMBINATIE VAN DAPAGLIFLOZINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN METFORMINE OF EEN FARMACEITISCH AANVAARDBAAR ZOUT DAARVAN, ZOALS BESCHERMD DOOR HET BASISOCTROOI EP 1506211B1; REGISTRATION NO/DATE: EU/1/13/900 20140121 |
0694547 | 2002/028 | Ireland | Start Trial | PRODUCT NAME: VALGANCICLOVIR (2-(2-AMINO-1,6-DIHYDRO-6-OXO-PURIN-9-YL)- METHOXY-3-HYDROXY-1-PROPANYL-L-VALINATE) AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; NAT REGISTRATION NO/DATE: 50/150/1 20020913; FIRST REGISTRATION NO/DATE: NL 25992 20010920; PAEDIATRIC INVESTIGATION PLAN: P/0220/2013 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.